Key facts
- This page summarizes Mark Plavsic's Form 4 filing for FATE THERAPEUTICS INC (FATE).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 11 Jan 2023, 15:07.
Mark Plavsic - 10 Jan 2023 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)
- Reporting relationship
- Chief Technical Officer
- Issuer ticker
- FATE
- Reported as of
- 10 Jan 2023
- Net transaction value
- -$17,910
- SEC form
- 4
- Accepted by SEC
- 11 Jan 2023, 15:07:13 UTC
- Prior SEC filing
- 06 Jul 2022
- Next SEC filing
- 25 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Cindy Tahl, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Plavsic filed Form 4 for FATE THERAPEUTICS INC (FATE) on 11 Jan 2023.
Change
- Previous filing in this sequence was filed on 06 Jul 2022.
- Current net transaction value: -$17,910.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FATE
transaction
Common Stock
Sale
- Transaction value
- $17,910
- Shares
- -3,418
- Change %
- -2.7%
- Price
- $5.24
- Shares after
- 123,705
- Date
- 10 Jan 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 8,325 shares of Common Stock underlying restricted stock units granted to the Reporting Person on January 25, 2022. This sale was made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Footnote F2
Represents the weighted average sale price of the shares sold from $5.12 to $5.37 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of he Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.